Loading...
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of a broad spectrum of tumor types, especially non–small-cell lung cancer (NSCLC). Despite the...
Na minha lista:
| Udgivet i: | J Hematol Oncol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7390199/ https://ncbi.nlm.nih.gov/pubmed/32723363 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00940-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|